Search research articles
Contact Us
Filters
Showing results (11-20 of 23) with videos related to
Page
of 3
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging
|
April 23, 2020
Key elements of preparedness for pandemic coronavirus disease 2019 (COVID-19) in nuclear medicine units
Majid Assadi, Ali Gholamrezanezhad, Narges Jokar, et al.
The British Journal of Radiology
|
September 7, 2021
Multimodal assessment of regional gray matter integrity in early relapsing-remitting multiple sclerosis patients with normal cognition: a voxel-based structural and perfusion approach
Hossein Shooli, Reza Nemati, Negar Chabi, et al.
Clinical Nuclear Medicine
|
October 28, 2024
Exploring the Potential Value of [ 68 Ga]Ga-FAPI-46 PET/CT for Molecular Assessment of Fibroblast Activation in Interstitial Lung Disease : A Single-Center Pilot Study
Mehrzad Bahtouee, Esmail Jafari, Mehdi Khazaei, et al.
Clinical Nuclear Medicine
|
June 21, 2021
Theranostic Approach in Breast Cancer: A Treasured Tailor for Future Oncology
Narges Jokar, Irina Velikyan, Hojjat Ahmadzadehfar, et al.
Clinical Nuclear Medicine
|
June 23, 2026
Preliminary Evaluation of 225Ac/177Lu-DOTATATE PRRT in Progressive Meningiomas: Efficacy, Dosimetry, and Imaging Insights
Reza Nemati, Malik E Juweid, Esmail Jafari, et al.
PET Clinics
|
May 31, 2021
Emerging Preclinical and Clinical Applications of Theranostics for Nononcological Disorders
Majid Assadi, Narges Jokar, Anna Yordanova, et al.
Nuklearmedizin. Nuclear Medicine
|
September 3, 2024
Prognostic Significance of Baseline Clinical and [68Ga]Ga-PSMA PET Derived Parameters on Biochemical Response, Overall Survival, and PSA Progression-Free Survival in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Undergoing [177Lu]Lu-PSMA Therapy
Esmail Jafari, Reyhaneh Manafi-Farid, Hojjat Ahmadzadehfar, et al.
PET Clinics
|
May 31, 2021
Theranostics in Brain Tumors
Hossein Shooli, Reza Nemati, Hojjat Ahmadzadehfar, et al.
Biomedical Physics & Engineering Express
|
June 30, 2026
Cycle-dependent variation of tumor absorbed dose rates in 177Lu-DOTATATE therapies
Ali Shabestani Monfared, Milad Peer-Firozjaei, Mohammad Reza Deevband, et al.
World Journal of Nuclear Medicine
|
September 5, 2022
Peptide Receptor Radionuclide Therapy Using <sup>177</sup> Lu-DOTATATE in Advanced Neuroendocrine Tumors (NETs) in a Limited-Resource Environment
Mohammadreza Kalantarhormozi, Samaneh Hassanzadeh, Seyed Javad Rekabpour, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 23) with videos related to
Sort By:
Page
of 3
European Journal of Nuclear Medicine and Molecular Imaging
|
April 23, 2020
Key elements of preparedness for pandemic coronavirus disease 2019 (COVID-19) in nuclear medicine units
Majid Assadi, Ali Gholamrezanezhad, Narges Jokar, et al.
The British Journal of Radiology
|
September 7, 2021
Multimodal assessment of regional gray matter integrity in early relapsing-remitting multiple sclerosis patients with normal cognition: a voxel-based structural and perfusion approach
Hossein Shooli, Reza Nemati, Negar Chabi, et al.
Clinical Nuclear Medicine
|
October 28, 2024
Exploring the Potential Value of [ 68 Ga]Ga-FAPI-46 PET/CT for Molecular Assessment of Fibroblast Activation in Interstitial Lung Disease : A Single-Center Pilot Study
Mehrzad Bahtouee, Esmail Jafari, Mehdi Khazaei, et al.
Clinical Nuclear Medicine
|
June 21, 2021
Theranostic Approach in Breast Cancer: A Treasured Tailor for Future Oncology
Narges Jokar, Irina Velikyan, Hojjat Ahmadzadehfar, et al.
Clinical Nuclear Medicine
|
June 23, 2026
Preliminary Evaluation of 225Ac/177Lu-DOTATATE PRRT in Progressive Meningiomas: Efficacy, Dosimetry, and Imaging Insights
Reza Nemati, Malik E Juweid, Esmail Jafari, et al.
PET Clinics
|
May 31, 2021
Emerging Preclinical and Clinical Applications of Theranostics for Nononcological Disorders
Majid Assadi, Narges Jokar, Anna Yordanova, et al.
Nuklearmedizin. Nuclear Medicine
|
September 3, 2024
Prognostic Significance of Baseline Clinical and [68Ga]Ga-PSMA PET Derived Parameters on Biochemical Response, Overall Survival, and PSA Progression-Free Survival in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Undergoing [177Lu]Lu-PSMA Therapy
Esmail Jafari, Reyhaneh Manafi-Farid, Hojjat Ahmadzadehfar, et al.
PET Clinics
|
May 31, 2021
Theranostics in Brain Tumors
Hossein Shooli, Reza Nemati, Hojjat Ahmadzadehfar, et al.
Biomedical Physics & Engineering Express
|
June 30, 2026
Cycle-dependent variation of tumor absorbed dose rates in 177Lu-DOTATATE therapies
Ali Shabestani Monfared, Milad Peer-Firozjaei, Mohammad Reza Deevband, et al.
World Journal of Nuclear Medicine
|
September 5, 2022
Peptide Receptor Radionuclide Therapy Using <sup>177</sup> Lu-DOTATATE in Advanced Neuroendocrine Tumors (NETs) in a Limited-Resource Environment
Mohammadreza Kalantarhormozi, Samaneh Hassanzadeh, Seyed Javad Rekabpour, et al.
Page
of 3